Content
All Posts > Content under Pharma/Biotech
Week In Review: China's Cytovant Signs $1 Billion Deal For Four Medigene I-O Candidates
Article By:
ChinaBio® Today
Read
Saturday, April 6, 2019 5:16 PM EDT
Cytovant Sciences, a China cell therapy startup, announced a $1 billion partnership with Germany's Medigene to develop four of Medigene's T cell immunotherapy products in China.
CytoDyn And Samsung BioLogics Enter Into Agreement To Manufacture $1 Billion Worth Of Leronlimab (PRO 140) To Meet Expected Demand For Future Revenues Post-Approval
Article By:
TalkMarkets Newswire
Read
Tuesday, April 2, 2019 5:00 AM EDT
CytoDyn, a late stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced the execution of a comprehensive strategic agreement with Samsung BioLogics.
In this article: CYDY
Biotech M&A Theme Builds Momentum
Article By:
Tarun Chandra, CFA
Read
Monday, April 1, 2019 12:14 PM EDT
The biotech sector has continued to participate in the market rally. One of the reasons is the strength in biopharma M&A activity. We briefly highlight some of the recent transactions and key events.
Week In Review: CanSino Nears $1 Billion Valuation Following Hong Kong IPO
Article By:
ChinaBio® Today
Read
Saturday, March 30, 2019 4:05 PM EDT
CanSino Biologics, a Tianjin vaccine company, rose 58% in its first trading day on the Hong Kong Exchange after staging its $161 million IPO. At the IPO price, CanSino was valued at $617 million; its market capitalization is now $968 million.
4 Small Biotech Stocks Likely To Witness More Upside In 2019
Article By:
Zacks Investment Research
Read
Saturday, March 30, 2019 5:45 AM EDT
Here are four companies from the biotech/drug sector which have performed well so far in 2019 and still hold upside. All these stocks have seen their share price and earnings estimates rise this year.
Is Cronos A Sell?
Article By:
Modest Money
Read
Friday, March 29, 2019 1:29 AM EDT
With the strong run-up in the Cannabis stocks on the bourses, we could see some profit booking. The Cronos Group cash position has improved after the Altria deal and revenue growth continues to be strong.
Cronos Group - Bullish Side Remains Intact
Article By:
Elliottwave Forecast
Read
Wednesday, March 27, 2019 10:44 PM EDT
Cronos Group earnings, from the Elliottwave perspective.
In this article: CRON
Here’s What 5 Analysts Think Of Aurora Cannabis Inc.
Article By:
The Daily Marijuana Observer
Read
Sunday, March 24, 2019 8:55 PM EDT
Whether or not you’re an existing investor in Aurora Cannabis Inc. (TSX:ACB) (NYSE:ACB) it can be nice to get a Wall Street analyst’s opinion on where they think things are headed. Even better than one analyst’s opinion is five analysts’ opinions.
Week In Review: Tianjin CanSino Staging $160.5 Million Hong Kong IPO
Article By:
ChinaBio® Today
Read
Saturday, March 23, 2019 5:05 PM EDT
Tianjin CanSino Biologics, a vaccine company, expects to raise up to $160.5 million in a Hong Kong IPO, which will begin trading on March 28. The company is developing 15 vaccine candidates for 12 disease areas.
In this article: MRK
Here’s What 3 Analysts Think Of Canopy Rivers Inc.
Article By:
The Daily Marijuana Observer
Read
Saturday, March 23, 2019 3:57 PM EDT
Whether you’re an existing or prospective investor in Canopy Rivers Inc., it can be nice to get a Wall Street analyst’s opinion on where they think things are headed. Even better than one analyst’s opinion is three analysts’ opinions.
In this article: CNPOF
4 Cannabis Stocks With Bright Futures Flying Under The Radar
Article By:
Technical420
Read
Friday, March 22, 2019 2:49 AM EDT
The cannabis sector represents an attractive growth opportunity and during the last year, we have seen a significant increase in the number of investors that are focused on this multi-billion-dollar market.